William Garrett Gray is CFO at Checkpoint Therapeutics, Inc. (CKPT). They have made 14 open-market trades across 1 company since 2020, most recently 2025-05-30.
CIK 0001692961
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CKPT | 1,446,322 | $6.2M |
Shares reported on the most recent Form 4, priced at the 2025-04-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CKPT | SELL | 2025-04-01 | 2025-04-03 | $4.05 | $50K | +0.0% | +3.2% | N/A |
| CKPT | SELL | 2025-02-06 | 2025-02-07 | $3.67 | $544K | -4.2% | +19.9% | +24.7% |
| CKPT | SELL | 2024-12-18 | 2024-12-20 | $4.01 | $2.2M | -1.1% | -18.7% | +10.0% |
| CKPT | SELL | 2024-06-26 | 2024-06-28 | $2.06 | $27K | +5.6% | +13.6% | +4.7% |
| CKPT | SELL | 2024-02-28 | 2024-03-01 | $2.07 | $4K | -13.3% | -10.2% | -16.0% |
| CKPT | SELL | 2024-02-01 | 2024-02-02 | $1.95 | $8K | +3.6% | +20.8% | -22.9% |
| CKPT | SELL | 2023-02-27 | 2023-03-03 | $4.88 | $27K | -26.3% | -50.8% | -48.6% |
| CKPT | SELL | 2023-02-01 | 2023-02-03 | $4.79 | $15K | -8.9% | -6.6% | -44.5% |
| CKPT | SELL | 2023-01-10 | 2023-01-12 | $6.75 | $13K | -27.5% | -32.3% | -72.4% |
| CKPT | SELL | 2022-03-10 | 2022-03-11 | $1.89 | $144K | +1.1% | -17.0% | -34.1% |
| CKPT | SELL | 2022-02-01 | 2022-02-02 | $2.51 | $186K | -13.7% | -33.2% | -44.4% |
| CKPT | SELL | 2021-02-04 | 2021-02-05 | $3.66 | $193K | +6.1% | -15.6% | -34.4% |
| CKPT | SELL | 2020-12-22 | 2020-12-23 | $2.79 | $7K | -6.4% | +28.8% | +21.4% |
| CKPT | SELL | 2020-05-21 | 2020-05-22 | $2.00 | $34K | -14.6% | -9.9% | -3.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.